Updated May 5, 2025, 10:24 PM UTC
| Income Statement - Metric | Q1 2018 | Q2 2018 | Q3 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD, thousands) | 192,508.00 | 624,799 | 164,010 | 195,885.00 | 203,191.00 | 802,804 | 201,317 | |||||||||||||||||||||||||
| Cost of goods sold (USD, thousands) | 28,054.00 | 96,576 | 24,757 | 29,843.00 | 32,398.00 | 35,988.00 | 122,986 | 30,709 | ||||||||||||||||||||||||
| Gross profit (USD, thousands) | 164,454.00 | 528,223 | 139,253 | 166,042.00 | 170,793.00 | 203,730.00 | 679,818 | 170,608 | ||||||||||||||||||||||||
| Research and development expense (USD, thousands) | 31,052.00 | 116,536 | 28,850 | 28,859.00 | 26,083.00 | 30,336.00 | 114,128 | 27,803 | ||||||||||||||||||||||||
| Selling, general and administrative expense (USD, thousands) | 124,105.00 | 451,958 | 125,621 | 132,084.00 | 130,392.00 | 141,510.00 | 529,607 | 144,290 | ||||||||||||||||||||||||
| Total operating expenses (USD, thousands) | 155,157.00 | 568,494 | 154,471 | 160,943.00 | 156,475.00 | 171,846.00 | 643,735 | 172,093 | ||||||||||||||||||||||||
| Operating income (loss) (USD, thousands) | 9,297.00 | (40,271) | (15,218) | 14,318.00 | 36,083 | (1,485) | ||||||||||||||||||||||||||
| Interest and dividend income (USD, thousands) | (5,870.00) | (20,560) | (5,923) | (5,882.00) | (5,890.00) | (5,552.00) | (23,247) | (5,066) | ||||||||||||||||||||||||
| Other expense, net (USD, thousands) | (73.00) | 195 | 60 | 135.00 | (118.00) | 778.00 | 855 | (578) | ||||||||||||||||||||||||
| Total other income (USD, thousands) | (5,943.00) | (20,365) | (5,863) | (5,747.00) | (6,008.00) | (4,752.00) | (22,370) | (5,644) | ||||||||||||||||||||||||
| Income (loss) before income taxes (USD, thousands) | 15,240.00 | (19,906) | (9,355) | 10,846.00 | 20,326.00 | 36,636.00 | 58,453 | 4,159 | ||||||||||||||||||||||||
| Income taxes (USD, thousands) | 477.00 | 1,247 | 650 | 1,053.00 | 1,829.00 | 1,412.00 | 4,944 | 1,167 | ||||||||||||||||||||||||
| Net income (loss) (USD, thousands) | 14,763.00 | (21,153) | (10,005) | 9,793.00 | 18,497.00 | 35,224.00 | 2,992 | |||||||||||||||||||||||||
| Balance Sheet - Metric | Q1 2018 | Q2 2018 | Q3 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| Cash and cash equivalents (USD, thousands) | 185,537 | 185,537 | 175,416 | 188,035 | 150,150 | 150,150 | 53,882 | |||||||||||||||||||||||||
| Investments, short-term (USD, thousands) | 274,838 | 274,838 | 265,945 | 251,629 | 263,475 | 295,396 | 295,396 | 315,307 | ||||||||||||||||||||||||
| Accounts receivable, net (USD, thousands) | 89,884 | 89,884 | 72,333 | 79,716 | 89,743 | 93,068 | 93,068 | 92,628 | ||||||||||||||||||||||||
| Inventories, net (USD, thousands) | 33,885 | 33,885 | 48,974 | 59,025 | 67,432 | 80,118 | 80,118 | 99,727 | ||||||||||||||||||||||||
| Prepaid expenses and other current assets (USD, thousands) | 9,595 | 9,595 | 9,546 | 28,755 | 14,358 | 12,074 | 12,074 | 10,135 | ||||||||||||||||||||||||
| Total current assets (USD, thousands) | 593,739 | 593,739 | 572,214 | 607,160 | 582,520 | 630,806 | 630,806 | 571,679 | ||||||||||||||||||||||||
| Investments, long-term (USD, thousands) | 9,143 | 9,143 | 27,803 | 26,344 | 70,995 | 70,995 | 44,831 | |||||||||||||||||||||||||
| Property and equipment, net (USD, thousands) | 39,984 | 39,984 | 52,281 | 61,701 | 67,447 | 71,925 | 71,925 | 77,175 | ||||||||||||||||||||||||
| Operating lease right-of-use assets (USD, thousands) | 22,667 | 22,667 | 22,248 | 22,189 | 21,811 | 23,314 | 23,314 | 24,972 | ||||||||||||||||||||||||
| Other non-current assets (USD, thousands) | 11,278 | 11,278 | 11,296 | 10,995 | 10,991 | 11,343 | 11,343 | 12,152 | ||||||||||||||||||||||||
| Total assets (USD, thousands) | 676,811 | 676,811 | 685,842 | 728,389 | 796,194 | 808,383 | 808,383 | 730,809 | ||||||||||||||||||||||||
| Accounts payable (USD, thousands) | 38,839 | 38,839 | 43,802 | 33,621 | 34,926 | 38,687 | 38,687 | 29,137 | ||||||||||||||||||||||||
| Accrued expenses (USD, thousands) | 39,266 | 39,266 | 28,370 | 32,036 | 39,338 | 49,814 | 49,814 | 34,333 | ||||||||||||||||||||||||
| Total current liabilities (USD, thousands) | 78,105 | 78,105 | 72,172 | 65,657 | 74,264 | 88,501 | 88,501 | 63,470 | ||||||||||||||||||||||||
| Operating lease liabilities, non-current portion (USD, thousands) | 24,846 | 24,846 | 24,500 | 24,512 | 25,218 | 30,039 | 30,039 | 31,488 | ||||||||||||||||||||||||
| Other non-current liabilities (USD, thousands) | 1,346 | 1,346 | 146 | 149 | 150 | 148 | 148 | - | ||||||||||||||||||||||||
| Total liabilities (USD, thousands) | 104,297 | 104,297 | 96,818 | 90,318 | 99,632 | 118,688 | 95,066 | |||||||||||||||||||||||||
| Common Stock (USD, thousands) | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 29 | ||||||||||||||||||||||||
| Additional paid-in capital (USD, thousands) | 917,107 | 917,107 | 944,298 | 983,791 | 1,021,970 | 981,043 | 981,043 | 924,409 | ||||||||||||||||||||||||
| Accumulated other comprehensive income (USD, thousands) | 800 | 800 | 124 | (115) | 1,700 | 536 | 536 | 227 | ||||||||||||||||||||||||
| Accumulated deficit (USD, thousands) | (345,423) | (345,423) | (355,428) | (345,635) | (327,138) | (291,914) | (291,914) | (288,922) | ||||||||||||||||||||||||
| Total stockholders' equity (USD, thousands) | 572,514 | 572,514 | 589,024 | 638,071 | 696,562 | 689,695 | 689,695 | 635,743 | ||||||||||||||||||||||||
| Total liabilities and stockholders' equity (USD, thousands) | 676,811 | 676,811 | 685,842 | 728,389 | 796,194 | 808,383 | 808,383 | 730,809 | ||||||||||||||||||||||||
| Cash Flow - Metric | Q1 2018 | Q2 2018 | Q3 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| Net income (loss) [USD, thousands] | 14,763.00 | (21,153) | (10,005) | 9,793.00 | 18,497.00 | 35,224.00 | 53,509 | 2,992 | ||||||||||||||||||||||||
| Depreciation and amortization [USD, thousands] | 817.00 | 2,846 | 839 | 1,383.00 | 1,850.00 | 2,478.00 | 6,550 | 3,044 | ||||||||||||||||||||||||
| Accretion of investment discount [USD, thousands] | - | (2,469) | (2,469) | (2,438.00) | (2,410.00) | (1,542.00) | (8,859) | (1,209) | ||||||||||||||||||||||||
| Stock-based compensation expense [USD, thousands] | 22,849.00 | 82,470 | 26,322 | 32,322.00 | 28,223.00 | 29,140.00 | 116,007 | 31,056 | ||||||||||||||||||||||||
| Provision (benefit) for estimated credit losses [USD, thousands] | - | - | (1,392) | 259.00 | 0.00 | 365.00 | (768) | 311 | ||||||||||||||||||||||||
| Other non-cash expenses [USD, thousands] | 716.00 | 1,987 | - | - | - | 411.00 | 1,517 | 512 | ||||||||||||||||||||||||
| Net cash provided by operating activities [USD, thousands] | 17,267.00 | 24,653 | 8,860 | (6,703) | ||||||||||||||||||||||||||||
| Purchases of property and equipment [USD, thousands] | (8,033.00) | (23,629) | (11,696) | (12,393.00) | (8,007.00) | (7,027.00) | (39,123) | (8,407) | ||||||||||||||||||||||||
| Purchases of investments [USD, thousands] | (143,936.00) | (281,189) | (55,739) | (56,296.00) | (225,505.00) | (80,814.00) | (418,354) | (16,719) | ||||||||||||||||||||||||
| Proceeds from sales or maturities of investments [USD, thousands] | 246.00 | 10,246 | 47,900 | 74,309.00 | 130,544.00 | 91,852.00 | 344,605 | 24,173 | ||||||||||||||||||||||||
| Purchases of strategic investments [USD, thousands] | 0.00 | (250) | - | - | - | - | (250) | (600) | ||||||||||||||||||||||||
| Net cash used in investing activities [USD, thousands] | (151,723.00) | (294,822) | (19,535) | 5,620.00 | (102,968.00) | 3,761.00 | (113,122) | (1,553) | ||||||||||||||||||||||||
| Proceeds from the exercise of stock options [USD, thousands] | 1,303.00 | 25,809 | 3,616 | 5,518.00 | 14,225.00 | (1,192.00) | 22,167 | 6,441 | ||||||||||||||||||||||||
| Accelerated share repurchase of common stock [USD, thousands] | - | - | - | - | - | - | (75,000) | (75,009) | ||||||||||||||||||||||||
| Payment of taxes on net share settlement of equity awards [USD, thousands] | (13,925.00) | (17,158) | (2,848) | (1,862.00) | (4,335.00) | 3,880.00 | (5,165) | (19,192) | ||||||||||||||||||||||||
| Net cash (used in) provided by financing activities [USD, thousands] | (10,115.00) | 13,950 | 768 | 7,087.00 | 9,890.00 | (70,138.00) | (52,393) | (87,760) | ||||||||||||||||||||||||
| Effect of exchange rate on cash [USD, thousands] | 211.00 | 164 | (214) | (10.00) | 272.00 | (166.00) | (118) | (252) | ||||||||||||||||||||||||
| (Decrease) increase in cash and cash equivalents [USD, thousands] | (144,360.00) | (256,055) | (10,121) | 12,619.00 | (40,523.00) | 2,638.00 | (35,387) | (96,268) | ||||||||||||||||||||||||
| Cash and cash equivalents at beginning of year [USD, thousands] | 441,592 | 441,592 | 185,537 | 185,537 | 185,537 | 185,537 | 185,537 | 150,150 | ||||||||||||||||||||||||
| Cash and cash equivalents at end of year [USD, thousands] | 185,537 | 185,537 | 175,416 | 188,035 | 147,512 | 150,150 | 150,150 | 53,882 | ||||||||||||||||||||||||
| Property and equipment included in accounts payable and accrued expenses [USD, thousands] | 4,018 | 4,018 | 5,458 | 3,868 | 3,456 | 3,386 | 3,386 | 3,272 | ||||||||||||||||||||||||
| Revenue by Geography - in Millions of USD | Q1 2018 | Q2 2018 | Q3 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| United States | 189.49 | 606.2 | 155.8 | 187.8 | 195.8 | 231.64 | 771.04 | - | ||||||||||||||||||||||||
| - All Other Countries | 3.11 | 18.6 | 8.2 | 8.1 | 7.4 | 8.06 | 31.76 | - | ||||||||||||||||||||||||
| Total Revenue | 192.5 | 624.8 | 164.0 | 195.9 | 203.2 | 239.7 | 802.80 | - | ||||||||||||||||||||||||
| KPIs - Metric (Unit, Scale) | Q1 2018 | Q2 2018 | Q3 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| Number of new U.S. centers that implant Inspire therapy (count) | - | 280 | 66 | 81 | 66 | - | 285 | - | ||||||||||||||||||||||||
| Number of total U.S. centers that implant Inspire therapy (count) | - | 1,180 | 1,246 | 1,316 | 1,371 | - | 1,435 | - | ||||||||||||||||||||||||
| Number of new U.S. sales territories (count) | - | 62 | 11 | 12 | 13 | - | 48 | - | ||||||||||||||||||||||||
| Number of total U.S. sales territories (count) | - | 287 | 298 | 310 | 323 | - | 335 | - | ||||||||||||||||||||||||
| Average BMI of patients treated with Inspire therapy (body mass index) | - | 29 | 29 | - | 29 | - | 29 | - |